Merck

A peer group tidy up

13/04/24 -"We have removed Novo Nordisk from the Merck peer group since the Danish obesity franchise company has reached a stellar valuation. This has had a significantly positive impact on our TP (+11%). In so ..."

PDF page sample
Pages
66
Language
English
Published on
13/04/24
Download
You may also be interested by these reports :
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...
04/11/26
The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being ...
04/11/26
“If a man knows not to which port he sails, no wind is favourable.” The Roman philosopher Seneca’s line may strike a chord with GSK’s (BUY; UK) ...
04/11/26
BioNTech’s Q3 operational performance exceeded expectations, driven by higher outlicensing sales from Bristol-Myers Squibb. 2026 sales guidance was ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO